Scientific Advisory Board
The Scientific and Clinical Council brings together high level experts in the therapeutic fields of Affichem.
Pr Wayne Bowen, PhD.
Professor of Biology at Brown University (Rhode Island) and expert in drug design applied to the field of the sigma receptors.
He has worked with the NIH (National Institute of Health), initially in the National Institute of Mental Health. He then created a unit on the biochemistry and pharmacology of receptors, and the unit was integrated into the Medicinal Chemistry laboratory of the NIDDK (National Institute of Diabete and Digestive and Kidney Diseases).
He is the inventor of 17 patents and author of more than 130 scientific publications. He is a member of the grant-awarding body of the National Institute of Drug Abuse and the National Institute of Mental Health of the NIH. He is member of the Society for Neuroscience and the American Association for Cancer Research.
Pr Mats Ulfendahl, PhD.
Doctor of medical science on the specific mechanisms of hearing. Professor in experimental audiology and otology at the Karolinska Institute in Stockholm.
Director of the “Center for Hearing and Research Communication” in the Karolinska Institute, his research group takes part in several international and European projects.
Joint author of over 100 scientific publications, Member of the Collegium Oto-Rhino-Laryngologicum Amicitiae Sacrum (CORLAS), and of the editorial board of “Acta Otolaryngologica” and “Noise and Health”, Member of the Society for Neurosciences and the European Neuroscience Association.
Pr Alain Ravaud, MD, PhD.
National and international expert in the treatment of cancer of the kidney and takes part in the therapeutic evaluation of urologic tumours and the early development in phase I trials.
Member of the American Society of Clinical Oncology, the American Association of Cancer Research, the European Society of Medical Oncology and the French Society of Cancerology. Member of the National Programme of Scientific Excellence of the cancer of the kidney in the INCA (the French National Institute of Cancer), vice president of the committee of rare tumours and member of the board of urologic tumours of the INCA. Member of the hematologic group of cancer treatment (GTOH) of the AFSSAPS and was a member of the group for therapeutic tests of the AFSSAPS. Member of the international, European or French boards of Pfizer, Bayer, Novartis and Wyeth.
Author of more than 50 articles on his work and participation in international studies.